Plus Therapeutics (PSTV) shares were sharply lower Tuesday after the biotechnology company said it priced a private placement of about 28 million common units to generate roughly $15 million in gross proceeds.
The offering was priced at $0.66 per unit, with about 22.7 million units to be sold for new capital and 5.3 million units offered in exchange for outstanding senior convertible notes, the company said.
Up to $3.2 million in senior convertible notes of the company are thus expected to be cancelled via the swap offer, Plus Therapeutics said.
Each unit consists of one common share or prefunded warrant, plus one series A warrant and one series B warrant to purchase one common share per warrant.
Net proceeds will be used for debt repayment, repurchase of certain outstanding warrants, general corporate purposes and working capital, the company said.
The offering is expected to close on or about Tuesday.
Price: 0.30, Change: -0.36, Percent Change: -55.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。